The decrease in estrogen levels and the change in the local bone microenvironment in postmenopausal women lead to vigorous osteoclastic activity in bone metabolism, leading to osteoporosis. Postmenopausal osteoporosis is an important cause and inducement of fractures, especially thoracolumbar osteoporotic compression fractures. Postmenopausal Fractures (PMOF) occur in 50% of postmenopausal women with osteoporotic fractures. In postmenopausal women, bone loss in the first 5 to 7 years increases at an annual rate of 1% to 5%, resulting in a reduction of trabecular bone and a tendency to Colles' fracture and vertebral fracture. In the following year, patients with hip fractures have a 12% to 15% chance of dying from respiratory or cardiovascular complications. In addition, about 50% of the survivors have sequelae such as lower limb motor ability decline, which caused a serious impact on the patient's quality of life and a huge medical economic burden. At present, the main treatment methods for PMOF are internal fixation resection combined with anti-bone loosening drug treatment. However, due to the change in bone loosening microenvironment in patients, the probability of postoperative bone nonunion is as high as 16.2%. Therefore, there is an urgent need to develop a highly effective therapy for postmenopausal osteoporotic fractures (PMOF).
This Research Topic aims to encourage and publish basic and clinical research on PMOF covering the advanced treatment methods, molecular mechanisms, and cross-disciplinary applications for PMOF so as to promote further treatment methods for PMOF putting into practice. We welcome submissions on the etiological prevention of PMOF, cutting-edge research on the treatment of PMOF, and the treatment of osteoporotic fractures resulting in bone nonunion.
In this Research Topic, we welcome researchers to submit Perspectives, Original Research, Reviews, and Case Reports, focusing on but not limited to the following topics:
• Update of epidemiological data and establishment of clinical prediction model of postmenopausal osteoporosis
• Pathogenesis, clinical screening, and markers for osteoporotic fracture
• Application of new techniques in thoracolumbar fracture surgery
• Advances in tissue engineering treatment of osteoporotic fractures, such as percutaneous autologous concentrated bone marrow injection, stem cell therapy, cytokine therapy, and scaffold loading materials
• Mechanism of postmenopausal osteoporotic fracture
• Molecular therapy for osteoporotic fractures
• Application of biomaterial in bone loosening fracture
The decrease in estrogen levels and the change in the local bone microenvironment in postmenopausal women lead to vigorous osteoclastic activity in bone metabolism, leading to osteoporosis. Postmenopausal osteoporosis is an important cause and inducement of fractures, especially thoracolumbar osteoporotic compression fractures. Postmenopausal Fractures (PMOF) occur in 50% of postmenopausal women with osteoporotic fractures. In postmenopausal women, bone loss in the first 5 to 7 years increases at an annual rate of 1% to 5%, resulting in a reduction of trabecular bone and a tendency to Colles' fracture and vertebral fracture. In the following year, patients with hip fractures have a 12% to 15% chance of dying from respiratory or cardiovascular complications. In addition, about 50% of the survivors have sequelae such as lower limb motor ability decline, which caused a serious impact on the patient's quality of life and a huge medical economic burden. At present, the main treatment methods for PMOF are internal fixation resection combined with anti-bone loosening drug treatment. However, due to the change in bone loosening microenvironment in patients, the probability of postoperative bone nonunion is as high as 16.2%. Therefore, there is an urgent need to develop a highly effective therapy for postmenopausal osteoporotic fractures (PMOF).
This Research Topic aims to encourage and publish basic and clinical research on PMOF covering the advanced treatment methods, molecular mechanisms, and cross-disciplinary applications for PMOF so as to promote further treatment methods for PMOF putting into practice. We welcome submissions on the etiological prevention of PMOF, cutting-edge research on the treatment of PMOF, and the treatment of osteoporotic fractures resulting in bone nonunion.
In this Research Topic, we welcome researchers to submit Perspectives, Original Research, Reviews, and Case Reports, focusing on but not limited to the following topics:
• Update of epidemiological data and establishment of clinical prediction model of postmenopausal osteoporosis
• Pathogenesis, clinical screening, and markers for osteoporotic fracture
• Application of new techniques in thoracolumbar fracture surgery
• Advances in tissue engineering treatment of osteoporotic fractures, such as percutaneous autologous concentrated bone marrow injection, stem cell therapy, cytokine therapy, and scaffold loading materials
• Mechanism of postmenopausal osteoporotic fracture
• Molecular therapy for osteoporotic fractures
• Application of biomaterial in bone loosening fracture
